Kidswell Bio Corporation [4584.T]
TOKYO, May 14 (Pulse News Wire) – Kidswell Bio Corporation (4584.T) resolved today at its board meeting to propose the reappointment of three directors at its annual shareholders' meeting scheduled for June 29, 2026. The proposed directors include Redar Lin Shinya, who will continue his role as president, Norikazu Eiki, and Sachiko Nishiohka, both of whom will also retain their positions.
Additionally, Minoru Tamayuki, whose term ends due to expiration, will step down. In conjunction with these appointments, the company implemented organizational changes aimed at enhancing operational and research strategies. Specifically, Kidswell's wholly-owned subsidiary, S-Quatre Co., Ltd., will focus on optimizing clinical development for cerebral palsy treatments while reinforcing human capital management and data sharing systems.
The restructuring includes merging functions within the Development Department, Production Department, and Research Department into a unified Research and Development Headquarters. Key roles such as Chief Executive Officer and various department heads have been reassigned to streamline operations and align strategic goals. Notably, Masubuchi Noriko, previously involved in global project management at Daiichi Sankyo, was appointed to lead the Translational Research division, bringing expertise across non-clinical and clinical phases of drug development.
🟡 Confidence: Standard AI-translated content.